{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036705","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.536644+00:00","generated_at":"2026-05-17T23:12:10.322776+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Prime Medicine reports ~$101.8M cash as of June 30; terminates ATM prospectus","bullets":["Preliminary cash, equivalents, and short-term investments ~$101.8M at June 30, 2025; plus $13.7M restricted cash.","Terminated ATM prospectus under S-3 effective July 30; no further sales pending new filing.","Sales agreement with Jefferies remains in force but ATM program currently inactive.","Updated July 2025 corporate presentation posted on company website; includes pipeline updates.","Company expects to report complete Q2 results in Form 10-Q; estimates subject to final adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036705","json":"https://secwatch.observer/filing/0001628280-25-036705.json","markdown":"https://secwatch.observer/filing/0001628280-25-036705.md","text":"https://secwatch.observer/filing/0001628280-25-036705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/0001628280-25-036705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025036705/prme-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:12:10.322776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}